AstraZeneca
PulseAugur coverage of AstraZeneca — every cluster mentioning AstraZeneca across labs, papers, and developer communities, ranked by signal.
- 2026-08-08 partnership AstraZeneca formed a joint venture with CSPC Pharmaceutical Group to focus on manufacturing and supply for the global market. source
- 2026-08-02 partnership AstraZeneca and Bristol Myers Squibb have reportedly held early-stage merger discussions. source
- 2026-08-02 partnership AstraZeneca has reportedly explored an acquisition of Bristol Myers Squibb. source
2 day(s) with sentiment data
-
Hong Kong tech hub selects 100 startups for long-term mentorship
Hong Kong's flagship tech hub, the Hong Kong-Shenzhen Innovation and Technology Park (HSITP), has selected approximately 100 start-ups to join its program. These selected companies will benefit from mentorship lasting f…
-
Arm Holdings CEO: AI will cure cancer in our lifetime · 2 sources tracked
The chief executive of Arm Holdings, René Haas, has expressed optimism that artificial intelligence will lead to a cure for cancer within our lifetimes. He believes that while current AI models struggle with the complex…
-
Akeso's Ivonescimab Outperforms AstraZeneca's Imfinzi in Cancer Trial
Chinese biopharmaceutical company Akeso announced that its immunotherapy drug, Ivonescimab, outperformed AstraZeneca's Imfinzi in a Phase 3 trial for biliary tract cancer. This trial, involving 682 patients, is the firs…
-
New LLM evaluation system for AI drug discovery agents validated by human experts
Researchers have developed a new LLM-based evaluation system to assess the performance of AI agents in drug discovery, addressing the limitations of traditional metrics and the scalability issues of human evaluation. Th…
-
AstraZeneca uses generative AI to discover novel drug scaffolds
AstraZeneca's recent study showcased the effectiveness of generative AI in identifying new and viable chemical scaffolds for clinical use. The success of these AI algorithms is contingent upon their training with vast d…
-
AstraZeneca develops LLM-powered Research Assistant for biomedical R&D
AstraZeneca has developed an internal LLM-based system called Research Assistant to aid scientists and clinicians in exploring biomedical data. This system offers a chat interface that integrates information from scient…
-
Global pharma giants invest in Chinese biotech for innovation and growth
Global pharmaceutical companies are increasing investments in Chinese biotech firms, seeking innovation and valuation growth. These partnerships aim to foster the development of Chinese companies, enabling them to compe…
-
Eli Lilly's Obesity Drugs Fuel 48% Revenue Growth, Retatrutide Trials Show Promise
Eli Lilly and Company reported a significant increase in its second-quarter revenue, reaching $23 billion, a 48% year-over-year growth. This surge was primarily driven by its GLP-1 drugs, Mounjaro and Zepbound, which ge…
-
AstraZeneca uses AI to speed up next-gen medicine design
AstraZeneca is leveraging artificial intelligence to accelerate the design of new medicines. The company is employing AI tools to enhance the drug discovery and development process, aiming to bring next-generation thera…
-
Data centers increasingly built with modular components due to electrician shortage · 3 sources tracked
SemiAnalysis has published an article detailing the increasing modularization of data center construction, comparing it to building with LEGO sets. This trend is driven by a critical shortage of electricians, which is p…
-
AstraZeneca, Bristol Myers Squibb reportedly explore merger talks
AstraZeneca and Bristol Myers Squibb have reportedly engaged in early-stage merger discussions, though the talks are not guaranteed to result in a transaction. Such a combination would create a pharmaceutical giant with…
-
Rolls-Royce leverages AI and defense trends for strong financial turnaround
Rolls-Royce is experiencing a significant turnaround, with its share price increasing tenfold under CEO Tufan Erginbilgiç. The company has raised its financial forecasts, projecting better cash flow and operating profit…
-
New Ebola vaccine enters UK human trials after rapid development
A new vaccine designed to combat the Bundibugyo strain of the Ebola virus has entered human trials in the UK. The first dose was administered to a volunteer named Ed Hunt at Oxford University. This rapid development, ac…
-
Hits Medicine licenses Shuwozhe® to AstraZeneca for up to $1.9B plus royalties
Hits Medicine has entered into a licensing agreement with AstraZeneca, granting the global rights to develop and commercialize its drug Shuwozhe®. In return, Hits Medicine will receive an upfront payment of $600 million…
-
China's drug industry accelerates AI-driven deal-making
China's pharmaceutical sector is increasingly leveraging artificial intelligence to discover and develop new drug candidates, aiming to fuel a new wave of domestic and international deals. The nation is already a signif…
-
Felon offers legal services using AI, raising ethical questions
A convicted felon in Arizona, despite lacking a law degree, has been offering legal consulting services under the name "Beyond Attorneys, LLC." He established websites and posted legal advice on TikTok, claiming to assi…
-
Barcelona emerges as a European life science hub, attracting investment and fostering China-Europe collaboration
Barcelona, Spain, is emerging as a significant European hub for life sciences, attracting substantial foreign investment and fostering a robust ecosystem of over 1,500 related companies. The region's success is attribut…
-
FDA Outpaces Pharma with Real-Time AI Clinical Trials
The FDA has successfully implemented a real-time clinical trial data system, allowing for immediate review of patient safety signals. This transformation was driven by the rapid, agency-wide adoption of an AI assistant …
-
Xinnuowei subsidiary secures $420M upfront payment from AstraZeneca
Xinnuowei's subsidiary, Jushi Bio, has received a $420 million upfront payment from AstraZeneca as part of a strategic collaboration. This partnership focuses on the discovery of novel peptide molecules and the developm…
-
Nvidia's AI investments reshape chip industry, surpassing major corporations
Nvidia's significant investments in AI infrastructure are reshaping the semiconductor landscape, with the company's market capitalization dwarfing that of major players like Ericsson and AstraZeneca combined. This surge…